TrueBlue price target lowered to $6 from $8 at BMO Capital

BMO Capital lowered the firm’s price target on TrueBlue (TBI) to $6 from $8 and keeps an Outperform rating on the shares. The company delivered a sizable margin-driven and organic-growth driven beat to consensus, and while many staffing names have been under pressure, TrueBlue seemed to fare better this quarter, the analyst tells investors in a research note. BMO adds it is cautiously optimistic that this “Canary in the Coal mine” will continue to inflect positively as conditions continue to stabilize within its end markets.